- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Intensity Therapeutics: Aktionäre bestätigen Direktor und Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
| Fr | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Intensity Therapeutics: INT230-6 Achieves Complete Responses In Murine Models Of MPNST | 1 | RTTNews | ||
| 30.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) | 69 | PR Newswire | SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 27.06. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.06. | Intensity Therapeutics shares plummet on proposed public offering | 2 | Seeking Alpha | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.06. | Intensity Therapeutics kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 11.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase ... | 278 | PR Newswire | SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the... ► Artikel lesen | |
| 06.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Intensity Therapeutics GAAP EPS of -$0.22 | 2 | Seeking Alpha | ||
| 13.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 53 | PR Newswire | Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treated
European Medicines Agency Authorization to initiate INVINCIBLE-4-Study... ► Artikel lesen | |
| 13.05. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 25.04. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | Why Intensity Therapeutics (INTS) Stock Is Getting Hammered | 3 | Benzinga.com | ||
| 25.04. | Intensity Therapeutics plunges on $2.35M public offering | 2 | Seeking Alpha | ||
| 25.04. | Intensity Therapeutics legt Bedingungen für Angebot über 2,35 Millionen US-Dollar fest | 2 | Investing.com Deutsch | ||
| 24.04. | INTENSITY THERAPEUTICS, INC. - S-1/A, General form for registration of securities | 6 | SEC Filings | ||
| 22.04. | INTENSITY THERAPEUTICS, INC. - S-1, General form for registration of securities | 5 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| NOVAVAX | 6,025 | -0,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| CRISPR THERAPEUTICS | 56,00 | 0,00 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| EDITAS MEDICINE | 2,360 | -0,46 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,700 | 0,00 % | Ginkgo Bioworks launches cost-effective ADME profiling service | ||
| NOVOCURE | 13,760 | -0,07 % | Novocure to Report Second Quarter 2025 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,230 | -4,17 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
| ADVERUM BIOTECHNOLOGIES | 2,400 | +2,56 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| EVOTEC | 7,456 | +0,59 % | Bayer, NetraMark, Evotec: Wie KI-Forschung jetzt Renditen beschleunigt und Ihr Depot optimieren könnte | Die Gesundheitsbranche wird 2025 von KI und Technologien radikal umgekrempelt. Während Pharmariesen unter Kostendruck und regulatorischen Stürmen ächzen revolutionieren Algorithmen die Arzneimittelentwicklung:... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| AVIDITY BIOSCIENCES | 33,740 | -0,88 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen |
Das Unternehmen INTENSITY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,325 Euro und damit -2,55 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.